


This listing of claims will replace all prior versions, and listings, of claims in the application:


**Listing of Claims:**

1-65. (Cancelled)

66. (Currently Amended) A compound formed by the process comprising the steps of:  
reacting a compound having the Formula:



wherein R5-R8 are each, independently, hydrogen, hydroxyl, halogen, substituted or unsubstituted alkyl, substituted or unsubstituted alkoxy, nitro, cyano or amide,  
with a ~~2-hydroxyalcohol~~ molecule having the formula:




wherein R1-R4 are each, independently, selected from the group consisting of H, substituted and unsubstituted C<sub>1</sub>-C<sub>6</sub> alkyl, substituted and unsubstituted C<sub>1</sub>-C<sub>6</sub> alkenyl, substituted and unsubstituted C<sub>1</sub>-C<sub>6</sub> alkoxy, substituted and unsubstituted C<sub>1</sub>-C<sub>6</sub> alkoxycarbonyl, substituted and unsubstituted C<sub>1</sub>-C<sub>6</sub> acyl, -(CH<sub>2</sub>)<sub>n</sub>-amino, -(CH<sub>2</sub>)<sub>n</sub>-aryl, -(CH<sub>2</sub>)<sub>n</sub>-heterocycle, and -(CH<sub>2</sub>)<sub>n</sub>-phenyl; n is an integer from 1 to 10,

and, treating said compound formed said reaction with ~~strong~~ acid and exposing the reaction to air.

67. (Currently Amended) The compound formed by the process in claim 66, wherein said ~~strong~~ acid is concentrated sulfuric acid or trifluoroacetic acid.

68. (Previously Presented) The compound formed by the process in claim 66, the compound having the formula:



or pharmaceutically acceptable salts thereof, or a regioisomeric mixture thereof, wherein

R1-R4 are each, independently, selected from the group consisting of H, substituted and unsubstituted C<sub>1</sub>-C<sub>6</sub> alkyl, substituted and unsubstituted C<sub>1</sub>-C<sub>6</sub> alkenyl, substituted and unsubstituted C<sub>1</sub>-C<sub>6</sub> alkoxy, substituted and unsubstituted C<sub>1</sub>-C<sub>6</sub> alkoxycarbonyl, substituted and unsubstituted C<sub>1</sub>-C<sub>6</sub> acyl, -(CH<sub>2</sub>)<sub>n</sub>-amino, -(CH<sub>2</sub>)<sub>n</sub>-aryl, -(CH<sub>2</sub>)<sub>n</sub>-heterocycle, and -(CH<sub>2</sub>)<sub>n</sub>-phenyl; or one of R1 or R2 and one of R3 or R4 form a fused ring, wherein the ring has 4-8 ring members;

R5-R8 are each, independently, hydrogen, hydroxyl, halogen, substituted or unsubstituted alkyl, substituted or unsubstituted alkoxy, nitro, cyano or amide; and

n is an integer from 1 to 10,

wherein R1, R2, R3, R4, R5, R6, R7 and R8 are not each H.

69. (Previously Presented) The compound formed by the process in claim 68, wherein R1 and R2 are alkyl, R3-R4 are, independently, H, OH, halogen, alkyl, alkoxy, substituted or unsubstituted acyl, substituted alkenyl or substituted alkyl carbonyl, and R7-R10 are each hydrogen.


70. (Previously Presented) The compound formed by the process in claim 68, wherein R1 and R2 are each hydrogen, one of R3 and R4 is methyl and the other is hydrogen and R5-R8 are each hydrogen.

71. (Previously Presented) The compound formed by the process in claim 68, wherein one of R1 and R2 is methyl and the other is hydrogen, one of R3 and R4 is methyl and the other is hydrogen and R5-R8 are each hydrogen.

72. (Currently Amended) The compound formed by the process in claim 68, wherein one of R1 and R2 is methyl and the other is are hydrogen, one of R3 and R4 is hydroxymethyl and the other is hydrogen and R5-R8 are each hydrogen.


73. (Previously Presented) The compound formed by the process in claim 68, wherein one of R1 and R2 is methyl and the other is hydrogen, R3 and R4 are each methyl and R5-R8 are each hydrogen.

74. (Previously Presented) The compound formed by the process in claim 68, the compound having the formula:




or pharmaceutically acceptable salt or a regioisomeric mixture thereof.

75. (Currently Amended) The compound formed by the process in claim 68, the compound having the formula:





or pharmaceutically acceptable salt or a regioisomeric mixture thereof.

76. (Previously Presented) The compound formed by the process in claim 68, the compound having the formula:





or pharmaceutically acceptable salt or a regioisomeric mixture thereof.

77. (Currently Amended) The compound formed by the process in claim 68, the compound having the formula:



or pharmaceutically acceptable salt or a regioisomeric mixture thereof.

78. (Currently Amended) The compound formed by the process in claim 68, the compound having the formula:



or pharmaceutically acceptable salt or a regioisomeric mixture thereof.

79. (Previously Presented) A pharmaceutical composition comprising a therapeutically effective amount of the compound formed by the process in claim 66 in combination with a pharmaceutically acceptable carrier.